**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/104

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | MYDAWA ROSUVASTATIN 10 mg TABLETS | | **REF. NO: NDQD2016061210** |
| **DATE RECEIVED:** 2016-06-23 | **LABEL CLAIM:** | Each film tablet contains: Rosuvastatin calcium equivalent to Rosuvastatin 10 mg | |
| **BATCH NO.:** R4015 | **PRESENTATION:** | Yellow coloured, circular shaped, biconvex faced tablets, plain on both faces, ten tablets packed in an aluminium blister strip and 3 such blister strips in a unit box. | |
| **MFG. DATE:** Aug. 2015 | **MANUFACTURER:** | THE MADRAS Pharmaceuticals. | |
| **EXP. DATE:**  Jul. 2017 | **ADDRESS:** | 137-B, Old Mahabalipuram Road, Karapakkam, Chennai - 600 096. INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | ION Kenya, Landmark Plaza, Arwings Khodek, Road, P. O. Box 46986-00100, Nairobi, KENYA. | |
|  | **TEST(S) REQUESTED:** | Uniformity of Content, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Content** | HPLC | Manufacturer's In-house Method | Acceptable value of 10 units is NMT 15% [n=10] | AV = 15% (n=10) | **COMPLIES** |
| **Identification** | HPLC | Manufacturer's In-house Method | RT of the Major Peak in the assay sample preparation corresponds to that in the assay standard preparation. | Super-imposable peak at RT 8.2 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Manufacturer's In-house Method | After 50 Mins No tablet is less than 75% | Average = 83% Range | **COMPLIES** |
| **Dissolution** | HPLC |  |  | 81 - 88% (RSD=3.8%, n=6) |  |
| **Assay** | HPLC | Manufacturer's In-house Method | 90.0 - 110.0% | 96.8% (RSD=0.8%, n=9) | **COMPLIES** |

**CONCLUSION:** The sample complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | DR. L. KARANJA | .......................................................... | DATE: 02/09/2016 |
| **ANALYST:** | DR. E. MBAE | .......................................................... | DATE: 02/09/2016 |
| **DIRECTOR** | DR. H. K. CHEPKWONY | .......................................................... | DATE: 02/09/2016 |
| **ANALYST:** | ERNEST MBAE | .......................................................... | DATE: 09-22-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 09-27-2016 |